Abstract

On March 5, 2012, the California Department of Public Health was notified of nine cases of clinically diagnosed fungal endophthalmitis at a single California ambulatory surgical center. The initial investigation, led by the Los Angeles County Department of Public Health, determined that in all cases patients had undergone vitrectomy with epiretinal membrane peeling using a dye called Brilliant Blue-G (BBG) from Franck's Compounding Lab, Ocala, Florida. This investigation has since expanded to involve intravitreal injection of triamcinolone-containing products from Franck's, an overall total of 33 cases in seven states, and collaboration between state and local health departments, CDC, and the Food and Drug Administration (FDA). This report describes the current investigative findings. Clinicians should be aware of the ongoing investigation and should avoid use of compounded products labeled as sterile from Franck's during this ongoing investigation.

Links

Publisher Full Text

Authors

Centers for Disease Control and Prevention (CDC)

Source

MMWR. Morbidity and mortality weekly report 61:17 2012 May 4 pg 310-1

MeSH

Ascomycota
Disease Outbreaks
Drug Compounding
Drug Contamination
Drug Labeling
Endophthalmitis
Fusariosis
Fusarium
Humans
Indicators and Reagents
Ophthalmologic Surgical Procedures
Pharmacies
Rosaniline Dyes
United States
Vitrectomy

Pub Type(s)

Journal Article

Language

eng

PubMed ID

22552209